T1	Participants 526 578	12-month, prospective, multicenter, open-label study
T2	Participants 580 655	Deceased-donor kidney transplant patients at protocol-specified risk of DGF
T3	Participants 1290 1396	Adverse events led to study drug discontinuation in 17â€ƒIE patients (26.2%) and 28 DE patients (37.8%) (NS)
